IL4R and Alzheimer disease: For patients with moderate to severe AD, a systemic therapy is available through the use of a monoclonal antibody against the interleukin‐4 (IL‐4) receptor alpha (IL‐4Rα); this anti‐IL‐4Rα antibody blocks the IL‐4/interleukin‐13 (IL‐13) binding to IL‐4 receptor types 1 and 2.14, 15, 16, 17, 18